RemeGen Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
3,146
- Stock Symbol
-
09995
- Investments
-
4
- Share Price
-
$8.50
- (As of Friday Closing)
RemeGen General Information
Description
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
Contact Information
Website
www.remegen.cnCorporate Office
- Number 58 Beijing Middle Road, Yantai Development Zone, Yantai Area
- China (China) Pilot Free Trade Zone
- Yantai, Shandong 264006
- China
Corporate Office
- Number 58 Beijing Middle Road, Yantai Development Zone, Yantai Area
- China (China) Pilot Free Trade Zone
- Yantai, Shandong 264006
- China
RemeGen Timeline
RemeGen Stock Performance
As of 13-Nov-2026, RemeGen’s stock price is $8.50. Its current market cap is $6.89B with 564M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.50 | $8.84 | $7.66 - $15.72 | $6.89B | 564M | 2.39M | $1.49 |
RemeGen Financials Summary
As of 30-Jun-2026, RemeGen has a trailing 12-month revenue of $1.14B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 8,757,414 | 5,959,317 | 2,024,806 | 4,004,574 |
| Revenue | 1,143,257 | 450,760 | 238,333 | 152,106 |
| EBITDA | 877,993 | 152,357 | (154,083) | (180,357) |
| Net Income | 831,957 | 98,681 | (204,637) | (213,605) |
| Total Assets | 1,449,340 | 1,035,927 | 753,211 | 779,878 |
| Total Debt | 45,776 | 314,678 | 365,818 | 177,748 |
RemeGen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
RemeGen Comparisons
Industry
Financing
Details
RemeGen Competitors (75)
One of RemeGen’s 75 competitors is Innocare, a Formerly VC-backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Innocare | Formerly VC-backed | Beijing, China | ||||
| Mersana Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Celldex | Formerly VC-backed | Hampton, NJ | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Connect Biopharmaceuticals | Formerly VC-backed | Taicang, China |
RemeGen Patents
RemeGen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026184099-A1 | Camptothecin compound and use thereof | Pending | 03-Mar-2025 | ||
| WO-2026158443-A1 | Method for treating non-small cell lung cancer using anti-pd-1 and vegf bispecific antibody | Pending | 23-Jan-2025 | ||
| WO-2026052046-A1 | Use of anti-claudin 18.2 antibody-drug conjugate for treating gastric cancer and/or gastroesophageal junction adenocarcinoma | Pending | 06-Sep-2024 | ||
| WO-2026025013-A3 | Combination therapies using cdk4 inhibitors and anti-her2 therapeutic agents for use in the treatment of cancer | Pending | 26-Jul-2024 | ||
| WO-2026025013-A2 | Combination therapy using cdk4 inhibitors for cancer treatments | Pending | 26-Jul-2024 | A61K31/506 |
RemeGen Signals
RemeGen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
RemeGen Investments (4)
RemeGen’s most recent deal was a IPO with ImmuneOnco for . The deal was made on 05-Sep-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ImmuneOnco | 05-Sep-2023 | IPO | Drug Discovery | ||
| Biocytogen Pharmaceuticals (Beijing) Co | 01-Sep-2022 | IPO | Pharmaceuticals | ||
| MabPlex | 01-Nov-2018 | Later Stage VC | Other Pharmaceuticals and Biotechnology | ||
| MabPlex | 25-Jun-2013 | Joint Venture | Other Pharmaceuticals and Biotechnology |
RemeGen ESG
Risk Overview
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
RemeGen Exits (1)
RemeGen’s most recent exit was on 01-Sep-2022 from Biocytogen Pharmaceuticals (Beijing) Co. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Biocytogen Pharmaceuticals (Beijing) Co | 01-Sep-2022 | Completed |
|
RemeGen FAQs
-
When was RemeGen founded?
RemeGen was founded in 2008.
-
Where is RemeGen headquartered?
RemeGen is headquartered in Yantai, China.
-
What is the size of RemeGen?
RemeGen has 3,146 total employees.
-
What industry is RemeGen in?
RemeGen’s primary industry is Drug Discovery.
-
Is RemeGen a private or public company?
RemeGen is a Public company.
-
What is RemeGen’s stock symbol?
The ticker symbol for RemeGen is 09995.
-
What is the current stock price of RemeGen?
As of 13-Nov-2026 the stock price of RemeGen is $8.50.
-
What is the current market cap of RemeGen?
The current market capitalization of RemeGen is $6.89B.
-
What is RemeGen’s current revenue?
The trailing twelve month revenue for RemeGen is $1.14B.
-
Who are RemeGen’s competitors?
Innocare, Mersana Therapeutics, Celldex, Astellas Pharma, and Connect Biopharmaceuticals are some of the 75 competitors of RemeGen.
-
What is RemeGen’s annual earnings per share (EPS)?
RemeGen’s EPS for 12 months was $1.49.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process